US grant for Immunomedics' breast cancer agent:
This article was originally published in Clinica
Immunomedics has received a US grant to test an imaging peptide for diagnosing breast cancer. The company has developed a peptide labelled with the nuclear isotope technetium-99m that binds to a receptor which is increased in breast and several other cancers. The Phase I study is expected to demonstrate the peptide's ability to image human breast cancer.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.